Experimental drug combo targets tough cancers in first human trial
NCT ID NCT06107868
Summary
This early-stage study is testing whether adding an experimental drug called RP-6306 to standard chemotherapy (carboplatin and paclitaxel) is safe for patients with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find the safest dose and schedule for the new combination. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.